The beneficial effects of anti-angiogenesis drugs in the treatment of the deadly brain tumors called glioblastomas appear to result primarily from reduction of edema — the swelling of brain tissue — and not from any direct anti-tumor effect. A new report describes how treatment with the experimental drug cediranib reduced edema and improved survival in three mouse models of glioblastoma.